Amlodipine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Amlodipine
- Amlodipine: From Hypertension to Recurrent Intracerebral Hemorrhage Prevention (Multi-Indication Screen)
Using the given evidence-pack-to-report template directly (it fully specifies format, extraction rules, and section order — no additional skill applies to this content-generation task). One structural note before the report: this evidence pack is a multi-indication screen (candidate_id: TW-DB00381-multi) — 10 candidate indications, each independently scored — rather than a single-indication pack. Following the template's extraction rule literally on predicted_indications[0] alone (brain stem infarction, L5/Hold, zero evidence) would bury the one indication that actually clears an evidence bar (rank 10, intracerebral hemorrhage, L2/Proceed with Guardrails). I've kept the template's exact section order and table formats, but built the Quick Overview around the best-evidenced candidate and added a full ranking table so nothing is omitted.
Amlodipine: From Hypertension to Recurrent Intracerebral Hemorrhage Prevention (Multi-Indication Screen)
One-Sentence Summary
Amlodipine is a long-acting dihydropyridine calcium channel blocker (CCB), originally indicated for hypertension and angina (no structured original-indication or Norway licensing data was returned in this pack). TxGNN screened 10 candidate new indications; the only one with actionable evidence is Intracerebral Hemorrhage (secondary prevention as part of a triple-pill antihypertensive strategy), supported by 6 clinical trials (including one completed Phase 3 RCT, n=1,671) and 8 publications. The remaining 9 candidates range from weak mechanistic extensions to apparent model/keyword noise with no supporting evidence.
Quick Overview
(Featured candidate: Intracerebral Hemorrhage — rank 10, the only indication reaching decision stage S2)
| Item | Content |
|---|---|
| Original Indication | Hypertension / Angina (general pharmacological knowledge — no original_indications or Norway license data was returned in this pack) |
| Predicted New Indication | Intracerebral Hemorrhage (secondary/recurrence prevention) |
| TxGNN Prediction Score | 99.79% (rank 2745) |
| Evidence Level | L2 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails (for this indication only — see full screen below) |
Full TxGNN Screening Summary (all 10 candidates)
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Brain stem infarction | 99.94% | L5 | S0 | Hold |
| 2 | Pulmonary hypertension, unclear/multifactorial mechanism (Group 5) | 99.91% | L5 | S0 | Hold |
| 3 | Pulmonary hypertension owing to lung disease/hypoxia (Group 3) | 99.91% | L5 | S0 | Hold |
| 4 | Malignant renovascular hypertension | 99.90% | L3 | S1 | Research Question |
| 5 | Malignant hypertensive renal disease | 99.90% | L5 | S0 | Hold |
| 6 | Cerebral artery occlusion | 99.89% | L2 | S1 | Research Question |
| 7 | Braddock syndrome | 99.88% | L5 | S0 | Hold |
| 8 | MRI defined brain infarct | 99.86% | L3 | S1 | Research Question |
| 9 | ABri amyloidosis | 99.84% | L5 | S0 | Hold |
| 10 | Intracerebral hemorrhage | 99.79% | L2 | S2 | Proceed with Guardrails |
Note: TxGNN score ranking does not track evidence quality here — the top-ranked prediction by score (brain stem infarction) has zero supporting trials or literature, while the lowest-ranked prediction (intracerebral hemorrhage) carries the strongest evidence.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available for this pack (original_moa: [Data Gap]). Based on known pharmacology, amlodipine is a long-acting dihydropyridine L-type calcium channel blocker; its efficacy in hypertension and angina is well established, and its blood-pressure-lowering effect is the mechanistic thread running through most of the candidates above.
Intracerebral hemorrhage (lead candidate): Amlodipine-class CCBs are already a standard component of combination antihypertensive regimens used for secondary prevention after stroke. The completed Phase 3 TRIDENT trial (NCT02699645, n=1,671) directly tested a fixed-dose "Triple Pill" (including a CCB) for reducing recurrent cerebrovascular events after intracerebral hemorrhage, and CASE-J (a large RCT) compared amlodipine-class CCB combination therapy against ARB monotherapy for cardiovascular/cerebrovascular event reduction. This is class-level and combination-therapy evidence rather than an amlodipine-monotherapy trial specifically for ICH, which is why the evidence level caps at L2 rather than L1.
Cerebral artery occlusion / MRI defined brain infarct: Preclinical rodent studies (transient MCAO models) show amlodipine, alone or combined with atorvastatin, reduces infarct size via antioxidant, anti-apoptotic, and anti-autophagic mechanisms. Clinical evidence here is indirect — large blood-pressure-control trials (e.g., STEP, n=8,000) that use brain-imaging or cerebrovascular endpoints as secondary outcomes, not amlodipine-specific interventional trials for acute occlusion.
Malignant renovascular hypertension: This is essentially a pharmacological extension within amlodipine's existing approved use (severe/resistant hypertension) rather than a genuine cross-domain repurposing; the two supporting citations are pediatric case reports that do not name amlodipine explicitly as the study drug.
Candidates assessed as Hold (no real signal): Brain stem infarction, Group 5 pulmonary hypertension, malignant hypertensive renal disease, Braddock syndrome, and ABri amyloidosis have no clinical trials or literature support. Notably, the 20 PubMed hits returned for Group 3 pulmonary hypertension (hypoxia/lung-disease-related) are general hypoxia-biology papers unrelated to amlodipine or CCB therapy — likely keyword-matching noise rather than evidence — and current ESC/ERS guidance actually advises against CCB use in hypoxia-driven pulmonary hypertension due to risk of worsening ventilation/perfusion mismatch. These candidates should not be advanced.
Clinical Trial Evidence
Intracerebral Hemorrhage (lead candidate)
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02699645 | Phase 3 | Completed | 1,671 | TRIDENT main trial: fixed low-dose "Triple Pill" BP-lowering strategy (incl. CCB) vs. standard care for preventing recurrent stroke after intracerebral hemorrhage — directly relevant, completed Phase 3 RCT |
| NCT07458880 | N/A | Recruiting | 140 | TRICH Score-guided triple antihypertensive therapy for BP control after ICH; follow-on to TRIDENT concept, no results yet |
| NCT03264352 | Phase 4 | Recruiting | 11,414 | Antihypertensive treatment in high-normal BP adults with Type 2 diabetes (IPAD); large but not ICH-specific |
| NCT00134160 | Phase 4 | Completed | 1,000 | High-dose ARB monotherapy vs. ARB + CCB combination for cardiovascular event reduction in elderly Japanese hypertensive patients |
| NCT03785067 | Phase 3 | Terminated | 1 | TRIDENT cognitive sub-study — terminated, enrollment of 1, not statistically usable |
| NCT03783754 | N/A | Terminated | 4 | TRIDENT MRI sub-study — terminated, enrollment of 4, not statistically usable |
Cerebral Artery Occlusion
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03015311 | N/A | Unknown | 8,000 | STEP trial: intensive vs. standard systolic BP targets in elderly hypertensive patients; status unknown, not amlodipine-specific |
| NCT02850081 | Phase 3 | Completed | 31 | Statin (not amlodipine) neuroprotection before carotid endarterectomy — indirectly related only |
| NCT00805311 | Phase 4 | Terminated | 400 | Carotid endarterectomy vs. optimal medical treatment; terminated, not amlodipine-specific |
| NCT03785067 | Phase 3 | Terminated | 1 | TRIDENT cognitive sub-study (see above) |
| NCT03783754 | N/A | Terminated | 4 | TRIDENT MRI sub-study (see above) |
MRI Defined Brain Infarct
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03015311 | N/A | Unknown | 8,000 | STEP trial (see above); uses MRI-related brain outcomes as one observation measure, status unknown |
Other 7 candidates (brain stem infarction, both pulmonary hypertension groups, malignant renovascular hypertension, malignant hypertensive renal disease, Braddock syndrome, ABri amyloidosis): Currently no related clinical trials registered.
Literature Evidence
Intracerebral Hemorrhage (lead candidate)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14717341 | 2003 | RCT | Hypertension Research | CASE-J trial rationale — large RCT comparing candesartan vs. CCB-based regimens for cardiovascular event reduction in high-risk hypertensive patients |
| 34994269 | 2022 | Review/Trial Rationale | Int J Stroke | TRIDENT trial rationale and design — single-pill CCB-containing combination for secondary BP-driven ICH prevention |
| 23053838 | 2013 | Review | Neurological Sciences | Role of antihypertensive choice (beta-blocker vs. alternatives) in acute hypertensive ICH outcomes |
| 3154329 | 1988 | Review | Cardiovascular Drugs and Therapy | Overview of CCB antihypertensive mechanism and use in severe hypertension |
| 17077518 | 2006 | Preclinical | Biol Pharm Bull | A different dihydropyridine CCB (benidipine) improves cerebral blood flow autoregulation in hypertensive rats — mechanistic class analogy only |
| 19299323 | 2009 | Case Report (Adverse Event) | Ann Pharmacother | Probable amlodipine-induced angioedema in a patient with hemorrhagic stroke — safety signal, not efficacy |
| 26698202 | 2015 | Case Report | BMJ Case Reports | PRES after rapid antihypertensive withdrawal post-bariatric surgery in a patient with prior ICH — unrelated context |
| 37489780 | 2024 | Case Report | Current Drug Safety | Tizanidine-induced hypotension in stroke patients — different drug, not directly relevant |
Cerebral Artery Occlusion
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21538457 | 2011 | Animal/Preclinical | J Neurosci Res | Amlodipine + atorvastatin reduce infarct size via anti-apoptotic/anti-autophagic mechanisms after transient MCAO in metabolic syndrome rats |
| 20971084 | 2011 | Animal/Preclinical | Brain Research | Synergistic neuroprotection of amlodipine + atorvastatin after stroke in Zucker metabolic rats |
| 21276424 | 2011 | Animal/Preclinical | Brain Research | Combined amlodipine + atorvastatin protects against ischemic stroke damage in Zucker rats |
| 17070425 | 2006 | Animal/Preclinical | Am J Hypertension | Amlodipine reduces stroke size in apolipoprotein E-deficient mice |
| 17904110 | 2007 | Animal/Preclinical | Brain Research | CCBs with antioxidative effects prevent neuronal damage after transient focal cerebral ischemia in rats |
Malignant Renovascular Hypertension
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16467664 | 2006 | Case Report | Journal of Hypertension | Pediatric case of severe renovascular hypertension from renal artery compression in tuberous sclerosis; management context only, amlodipine not named as study drug |
| 15113447 | 2004 | Case Report | BMC Nephrology | Hyponatremic hypertensive syndrome presenting as malignant hypertension in an 18-month-old; amlodipine not named as study drug |
Pulmonary Hypertension Owing to Lung Disease/Hypoxia (Group 3)
20 PubMed records were returned by keyword search, but on review all are general hypoxia-biology or oncology-hypoxia papers (e.g., cerebral hypoxia and aging, HIF-1α signaling in cancer, altitude physiology) with no direct discussion of amlodipine, CCBs, or pulmonary hypertension treatment. These are assessed as keyword-matching noise rather than genuine evidence and are not counted toward the evidence level; current treatment guidance (ESC/ERS) advises against CCB use in this indication. No relevant literature identified.
Other candidates (brain stem infarction, Group 5 pulmonary hypertension, malignant hypertensive renal disease, Braddock syndrome, MRI defined brain infarct, ABri amyloidosis): Currently no related literature available.
Norway Market Information
No marketing authorizations were found for amlodipine in this dataset — market status is recorded as Not Marketed, with 0 authorizations on file. No product/dosage-form/indication records are available to tabulate.
Safety Considerations
Please refer to the package insert for safety information. (No structured warnings, contraindications, or drug-interaction data were returned for this drug in the current pack; a blocking data gap — TFDA/label warnings and contraindications — was flagged and remains unresolved as of the data cutoff.)
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Intracerebral Hemorrhage secondary prevention only) — Hold (for the other 9 screened candidates)
Rationale:
- Intracerebral hemorrhage is the only candidate supported by a completed Phase 3 RCT (TRIDENT, n=1,671) and corroborating class-level trial/literature evidence, justifying guarded advancement rather than outright hold.
- Cerebral artery occlusion and MRI defined brain infarct (Research Question) have credible preclinical/mechanistic signal but no amlodipine-specific interventional trial, and malignant renovascular hypertension is a pharmacological extension of an already-approved use rather than novel repurposing — all three need targeted evidence review before moving past S1.
- The remaining 5 candidates (brain stem infarction, both pulmonary hypertension groups, malignant hypertensive renal disease, Braddock syndrome, ABri amyloidosis) have no supporting trials or literature, and in the case of Group 3 pulmonary hypertension the returned literature is unrelated noise; these should remain on Hold.
To proceed, the following is needed:
- Resolution of DG001 (TFDA/label warnings and contraindications) — currently a blocking gap for any safety pre-assessment (S1 gate).
- Resolution of DG002 (mechanism of action) to support the mechanistic-plausibility analysis with primary source data rather than general pharmacological knowledge.
- For the lead candidate (intracerebral hemorrhage): amlodipine-specific (not combination-only) outcome data from TRIDENT if/when available, plus a formal indication-specific safety review given the drug is not currently marketed in Norway.
- For the three Research Question candidates: a targeted literature/trial search using amlodipine-specific search terms (rather than CCB-class terms) to confirm or rule out promotion to S2.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.